Predicting the Placebo response in OA to Improve the Precision of the Treatment Effect Estimation - Tools4Patient
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 | Antimicrobial Agents and Chemotherapy
Supplemental Materials for Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study - European Journal of Cancer
Causal Inference from Pragmatic Trials.
MAVYRET Efficacy and Clinical Study Designs
What is a PP Population, or 'Per Protocol' Population in a Clinical Trial? - Quantics Biostatistics
View Image
Screening: the information individuals need to support their decision: per protocol analysis is better than intention-to-treat analysis at quantifying potential benefits and harms of screening | BMC Medical Ethics | Full Text
Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial - Clinical Microbiology and Infection
Per-Protocol and Pre-Defined population analysis of the LINC study - Resuscitation
CONSORT diagram. ITT, intention to treat; PP, per protocol. | Download Scientific Diagram
1745-6215-14-371-S1
Souvenaid • The Journal of Prevention of Alzheimer's Disease
1 PROTECT II Prospective Multicenter Randomized Trial Comparing
Efficacy and tolerability of racecadotril in acute diarrhea in children - Gastroenterology
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
Amlodipine Besylate Vs. Candesartan Cilexetil
Discordance between reported intention-to-treat and per protocol analyses - Journal of Clinical Epidemiology
CONSORT Flow Diagram. *Per protocol population was used for applicable... | Download Scientific Diagram
AUTH/2607/5/13 - Pfizer v GlaxoSmithKline
Results - Clinical Review Report: Ocrelizumab (Ocrevus) - NCBI Bookshelf
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial - The Lancet Infectious Diseases
